PART 1 - IMMUNOLOGY. 1.1 The keratinocyte in epidermal renewal and defense. 1.2 Unravelling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. 1.3 Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. 1.4 Immunohistochemical evaluation of filaggrin polyclonal antibody in atopic and normal beagles. 1.5 The histamine H4 receptor as a new target for treatment of canine inflammatory skin diseases. 1.6 Levels of house dust mite-specific serum immunoglobulin E (IgE) in different cat populations using a monoclonal based anti-IgE enzyme-linked immunosorbent assay. 1.7 Canine epitheliotropic cutaneous T-cell lymphoma: an investigation of T-cell receptor immunophenotype, lesion topography and molecular clonality. 1.8 Indolent cutaneous T-cell lymphoma presenting as cutaneous lymphocytosis in dogs. 1.9 Use of the D-dimer assay for diagnosing thrombosis in cases of canine cutaneous vasculitis. PART 2 - THERAPY. 2.1 New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. 2.2 Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. 2.3 The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study. PART 3 - INFECTIOUS DISEASES. 3.1 Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. 3.2 Advances in the pathogenesis of canine leishmaniosis: epidemiologic and diagnostic implications. 3.3 The Staphylococcus intermedius group of bacterial pathogens: species re-classification, pathogenesis and the emergence of meticillin resistance. 3.4 Risk of colonization or gene transfer to owners of dogs with meticillin-resistant Staphylococcus pseudintermedius. 3.5 Staphylococcus intermedius binding to immobilized fibrinogen, fibronectin and cytokeratin in vitro. 3.6 Presence of Bartonella species and Rickettsia species DNA in the blood, oral cavity, skin and claw beds of cats in the United States. PART 4 - PARASITOLOGY. 4.1 Flea and tick control in the st century: challenges and opportunities. 4.2 Treatment of canine generalised demodicosis with a ’spot-on’ formulation containing % moxidectin and .5% imidacloprid (Advocate, Bayer Healthcare). 4.3 Treatment of canine generalized demodicosis: a blind, randomized clinical trial comparing the efficacy of Advocate (Bayer Animal Health) with. PART 5 - OTOLOGY. 5.1 Anatomy and physiology of the canine ear. 5.2 Histological changes in the external ear canal of dogs with otitis externa. 5.3 In vitro and in vivo evaluation of a potentiated miconazole aural solution in chronic Malassezia otitis externa in dogs. PART 6 - SKIN BIOLOGY. 6.1 The molecular logic of pemphigus and impetigo: the desmoglein story. 6.2 Dermatoses affecting desmosomes in animals: a mechanistic review of acantholytic blistering skin diseases. 6.3 Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy. 6.4 Development of an enzyme-linked immunosorbent assay for detection of circulating IgG autoantibodies against canine desmoglein in dogs with pemphigus. 6.5 Canine hair-follicle keratinocytes enriched with bulge cells have the highly proliferative characteristic of stem cells. 6.6 Defining the complex epithelia that comprise the canine claw with molecular markers of differentiation. 6.7 A two-dimensional morphological study of corneocytes from healthy dogs and cats and from dogs with atopic dermatitis. 6.8 Survivin expression in canine epidermis and in canine and human cutaneous squamous cell carcinomas. 6.9 Hereditary cutaneous mucinosis in shar pei dogs is associated with increased hyaluronansynthase-2 mRNA transcription by cultured dermal fibroblasts PART 7 - EQUINE DERMATOLOGY. 7.1 Biomechanical and molecular characteristics of hereditary equine regional dermal asthenia in Quarter Horses. 7.2 Cutaneous vasculitis in equines: a retrospective study of cases. 7.3 Intradermal testing of horses with and without insect bite hypersensitivity in the Netherlandsusing an extract of native Culicoides species. 7.4 Effects of dexamethasone and hydroxyzine treatment on intradermal testing and allergen-specific IgE serum testing results in horses. 7.5 An open study to evaluate topical treatment of equine chorioptic mange with shampooing and lime sulphur solution. PART 8 - WORKSHOP REPORTS. 8.1 Otitis media: how common and how important?. 8.2 Advances in ectoparasite control and prevention. 8.3 Atopic dermatitis and food allergy: are they the same? 8.4 Treatment of hyperadrenocorticism and its complications. 8.5 Pocket pet dermatology. 8.6 Nutraceuticals, traditional Chinese medicine, and non traditional therapies. 8.7 New diagnostic tests in dermatology. 8.8 Novel forms of immunotherapy for allergic diseases. 8.9 Advances in topical therapy. 8.10 Topical and systemic antimicrobial therapy for ear infections. 8.11 Variabilities of vasculitis. 8.12 What’s new in skin neoplasia? 8.13 Dust mite and storage mite hypersensitivity: what does it mean? 8.14 Cytology and culture: how they affect treatment decisions. Index.